Non-Wilms Renal Tumors
Clinical And Molecular Profiles
While Wilms tumor represents the majority of childhood renal malignancies, distinct non-Wilms entities predominate in specific age groups and possess unique molecular drivers.
| Tumor Type | Demographics | Molecular / Genetic Hallmark | Characteristic Features |
|---|---|---|---|
| Congenital Mesoblastic Nephroma (CMN) | Infancy (<3 months) | Classic: EGFR internal tandem duplications (ITDs).Cellular: t(12;15) ETV6-NTRK3 fusion. | Cellular type histologically resembles infantile fibrosarcoma. |
| Clear Cell Sarcoma Of The Kidney (CCSK) | Peak age 3-5 years (Male:Female 2:1) | BCOR ITDs (80-90%).t(10;17) YWHAE-NUTM2 fusion (5-10%). | High propensity for bone metastasis at presentation; brain metastasis at recurrence. |
| Rhabdoid Tumor Of The Kidney (MRT) | Median age 1 year | SMARCB1/INI1 (22q11-12) deletion or mutation. | Extremely poor prognosis (~25% survival). Brain metastases common. Associated with atypical teratoid/rhabdoid tumors. |
| Renal Cell Carcinoma (RCC) | Adolescents / Young Adults | "Translocation" type involving TFE3 gene on X chromosome. | Distinct from adult clear cell variant. Constitutes 5-6% of pediatric renal tumors. |
Management Modalities
- Congenital Mesoblastic Nephroma: Complete nephrectomy typically curative without adjuvant therapy. Adjuvant chemotherapy (vincristine, dactinomycin, doxorubicin/cyclophosphamide) considered for Stage III cellular CMN. TRK inhibitors (larotrectinib) indicated for unresectable or recurrent NTRK3-translocated tumors.
- Clear Cell Sarcoma Of The Kidney: Requires nephrectomy, radiation therapy, and 24-week multiagent chemotherapy (cyclophosphamide, etoposide, vincristine, doxorubicin).
- Rhabdoid Tumor Of The Kidney: Aggressive multimodal therapy required. Intensive chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, carboplatin, etoposide) combined with radiation therapy and maximal surgical resection.
- Renal Cell Carcinoma: Surgical resection remains the therapeutic mainstay. Multitargeted tyrosine kinase inhibitors (axitinib) and immune checkpoint inhibitors (nivolumab) currently evaluated for recurrent or metastatic translocation RCC.